Thus, inhibition of TLR4 signaling has been shown as an attractive therapeutic strategy for treatment of obesity-induced insulin resistance and adipocytes mediated chronic inflammation. Here, TLR4 is linked to obesity due to melanocortin 4 receptor deficiency.